Severe Acute Respiratory Syndrome (SARS)

---

I. Introduction & Problem Statement

Severe Acute Respiratory Syndrome (SARS) is a highly contagious, notifiable viral respiratory illness. It is characterized by an acute, overwhelming inflammatory syndrome that leads to massive pulmonary capillary leakage. This systemic inflammatory storm inevitably results in severe interstitial and alveolar pulmonary edema, rapidly suffocating the patient.

The 2002-2004 Epidemic: A Global Crisis

The sudden emergence of SARS represented the first major global pandemic of the 21st century, fundamentally altering modern infectious disease protocols and international travel regulations.

• Origin and Initial Spread: The earliest recognized case was traced retrospectively to a healthcare worker in Foshan, Guangdong Province, China, in November 2002. The disease was officially recognized globally in early 2003 after a physician unknowingly carried the virus to the Metropole Hotel in Hong Kong, sparking a massive super-spreader event.
• Rapid Global Dissemination: Fueled by modern globalization and international flights, the virus spread from the Hong Kong hotel corridor to Singapore, Vietnam, Taiwan, and as far as Toronto, Canada, within a matter of days.
• Epidemiological Statistics: By August 2003, when the primary outbreak was contained, exactly 8,422 cases were reported to the World Health Organization (WHO) across 30 different countries. This resulted in approximately 744 to 916 confirmed fatalities.
• Case Fatality Rate (CFR): The global CFR hovered alarmingly between 10% to 14%. However, this mortality was sharply age-dependent, rising past 50% in the elderly.
• Current Status: Rigorous global public health interventions successfully eradicated the virus from the human population. Since 2004, NO natural SARS outbreaks have been reported anywhere in the world. (A few subsequent cases were strictly related to laboratory laboratory accidents).

---

II. Etiology & Zoonotic Origins

The Pathogen

SARS is caused by the SARS-associated coronavirus (SARS-CoV-1). This is an enveloped, positive-sense, single-stranded RNA virus belonging to the Coronaviridae family. Prior to 2002, coronaviruses were only known to cause mild, self-limiting upper respiratory tract infections (the common cold) in humans.

Zoonotic Transmission Cycle

SARS-CoV-1 is a classic zoonosis (a disease transmitted from animals to humans). The emergence of the virus is a textbook example of viral recombination and interspecies jumping.

• Natural Reservoir: Extensive virological tracing led researchers to cave-dwelling horseshoe bats (genus Rhinolophus) in Yunnan, China. Multiple SARS-related coronaviruses continuously recombine and evolve within this specific bat population without making the bats sick.
• Intermediary Amplifying Hosts: Direct bat-to-human transmission is rare. In 2003, researchers tested animals in Guangdong's crowded live animal "wet markets." They successfully isolated an almost genetically identical virus from masked palm civets and raccoon dogs sold for human consumption.

Environmental Survival

The SARS virus is exceptionally resilient, which heavily contributed to its ability to cause massive hospital outbreaks and environmental spread.

• It can survive for hours on common dry surfaces outside the human body.
• It can survive at least 24 hours on plastic surfaces at room temperature.
• It can survive for up to four days in human waste (feces and urine), which led to massive plumbing-related aerosolized outbreaks (such as the infamous Amoy Gardens apartment complex outbreak in Hong Kong).
• It can live for highly extended periods in cold environments, preserving its viability in refrigerated conditions.

---

III. Transmission & Infection Control

SARS is classified as a strict notifiable infectious disease under the International Health Regulations (IHR 2005). This is due to its terrifying potential for super-spreading events, where a single highly infectious individual transmits the virus to dozens of others in a single setting.

Modes of Transmission (MOT)

• Primary Mode: The virus is primarily spread via direct or indirect contact with large respiratory droplets (generated by coughing or sneezing) or via fomites (contaminated environmental surfaces).
• Aerosol-Generating Procedures (AGPs): This is a critical clinical concept. Medical procedures such as endotracheal intubation, bronchoscopy, CPR, and nebulizer treatments artificially aerosolize the virus, turning heavy droplets into microscopic, floating droplet nuclei that bypass standard surgical masks. This high-risk aerosolization heavily amplified transmission in hospitals. Consequently, Healthcare Workers (HCWs) accounted for a staggering 21% of all global SARS cases!

Epidemiological Timing of Transmission

Understanding when a patient is most infectious is crucial for quarantine protocols.

• Unlike typical viruses that peak in shedding on day 1 or 2, maximum virus excretion from the respiratory tract in SARS-CoV-1 occurs on Day 10 of the illness, and then steadily declines.
• Transmission efficiency is greatest following exposure to severely ill patients experiencing rapid clinical deterioration during the second week of illness.
• Crucially, there is no evidence that a patient can transmit the infection 10 days after their fever has completely resolved.

Infection Control & Public Measures

Without a vaccine or cure, the 2003 outbreak was halted entirely through medieval-style public health measures enhanced by modern epidemiology:

• Prompt identification, triaging, and strict isolation of suspected cases.
• Strict respiratory isolation utilizing airborne precautions (mandatory use of N95 particulate respirators, eye protection/face shields, gowns, gloves, and placing patients in Negative Pressure isolation rooms).
• Simple but aggressive hygienic measures: Frequent, fastidious hand washing (especially after touching patients or removing PPE), and avoiding touching the facial mucosa with unwashed hands.
• Implementation of mandatory exit screening (temperature checks) of international travelers at airports to sever the chains of global spread.

---

IV. Clinical Manifestations & Disease Phases

The Incubation Period (IP) ranges broadly from 1 to 16 days, but the vast majority of patients fall into a tighter window of 2 to 7 days (averaging 3-5 days). Following the incubation period, the disease reliably follows a distinct triphasic clinical course.

Classification by Clinical Phase

Classification by Disease Severity

• Mild Cases (Majority): Present with the aforementioned mild clinical symptoms, a relatively short disease duration, and no significant long-term respiratory complications.
• Severe Cases (10-20%): Characterized by rapid, aggressive disease progression. These patients suffer massive alveolar damage leading directly to Acute Respiratory Distress Syndrome (ARDS), inevitably requiring invasive mechanical ventilatory support in an ICU setting.

Physical Examination Findings

• Auscultation: The chest may initially sound deceivingly clear, but as the disease progresses, auscultation reveals fine, moist rales (crackles) predominantly in the lower lung fields.
• Percussion/Palpation: Dullness to percussion and bronchial breath sounds indicating frank lung consolidation may be observed in severe cases with heavy exudate.
• Inspection: Visible tachypnea (rapid, shallow breathing), nasal flaring, intercostal retractions, and the use of accessory respiratory muscles indicating impending respiratory failure.

---

V. Laboratory & Radiographic Diagnosis

Laboratory Abnormalities

Routine blood work reveals a specific pattern indicative of severe viral stress and widespread tissue destruction.

Radiographic Findings (Chest X-Ray / CT Scan)

Radiographic progression mirrors the clinical deterioration of the patient.

• Early Findings: Typically begin as small, unilateral, focal patchy shadowing or ground-glass opacities, often located in the peripheral or lower lung zones.
• Progression: Over the course of just 1-2 days, these opacities rapidly progress to become bilateral, generalized, and confluent, featuring severe interstitial and alveolar infiltration.
• Conclusion: The overall radiographic features are perfectly consistent with severe atypical viral pneumonia progressing to ARDS.

---

VI. Case Definition & Diagnostic Confirmations

Clinical Case Definition (Suspect Case)

A patient meets the clinical criteria for SARS if they present with the following combination:

1. A reliable history of fever, or a currently documented high fever (> 38°C) AND
2. One or more symptoms of lower respiratory tract illness (such as cough, difficulty breathing, shortness of breath) AND
3. Radiographic evidence (CXR/CT) of lung infiltrates consistent with pneumonia or ARDS (or corresponding autopsy findings) AND
4. No alternative diagnosis that fully explains the illness (e.g., ruling out bacterial pneumonia or influenza).

Laboratory Confirmation

Because the positive predictive value of a SARS-CoV test is extremely low in the absence of an active global outbreak (leading to false positives), diagnosis must be independently verified by maximum-security WHO reference laboratories. Official confirmation requires ONE of the following strict criteria:

---

VII. Management & Reparatory Support

Despite massive global research efforts, there is NO specific antiviral therapy that has demonstrated clear, reproducible efficacy against SARS-CoV-1, and there is NO available vaccine. Furthermore, because SARS is a viral pathogen, broad-spectrum antibiotics are completely ineffective (though they may be given prophylactically to prevent secondary bacterial superinfections).

Therefore, the absolute mainstay of treatment is purely high-level Supportive Care designed to keep the patient alive while the viral illness naturally runs its course.

General Supportive Measures

• Intravenous Fluid Administration: Meticulously calculated to maintain systemic hydration and blood pressure without overloading the already leaking, edematous pulmonary capillaries.
• Electrolyte Monitoring: Frequent laboratory checks to correct life-threatening imbalances (e.g., hypokalemia or hyponatremia caused by severe diarrhea).
• Nutritional Support: Enteral or parenteral feeding for sedated ICU patients.
• Comorbidity Management: Aggressively controlling underlying contributing factors such as diabetes, hypertension, or heart disease.

Reparatory (Respiratory) Support Protocols

This is the most critical intervention for severe cases facing respiratory collapse.

• Supplemental Oxygen: Ranging from nasal cannula to high-flow oxygen masks to correct acute hypoxemia.
• Mechanical Ventilation: Required in 20% to 30% of hospitalized patients who progress to severe respiratory failure. The patient is sedated, paralyzed, and intubated.
• Protective Ventilation Strategies: Crucially, ventilators must be set to deliver low tidal volumes (e.g., 6 mL/kg of ideal body weight). Because the ARDS lung is stiff, inflamed, and non-compliant, forcing large volumes of air into it will cause devastating barotrauma (blowing out the alveoli).
• Prone Positioning: Patients with moderate to severe ARDS must be physically flipped over into the prone position (face down) for 12-16 hours a day to improve oxygenation. (Deep Physiology: Proning relieves the heavy physical compression exerted on the posterior, dependent lung zones by the heart and abdominal organs. This pops open collapsed posterior alveoli, massively improving V/Q (Ventilation/Perfusion) matching and saving the patient's life!)
• ECMO (Extracorporeal Membrane Oxygenation): Venovenous (VV-ECMO) acts as an artificial, external lung. It pumps the patient's blood out, oxygenates it through a membrane, and pumps it back in. This may improve survival in the most extreme, refractory cases, though strict adherence to indication/contraindication criteria is absolutely required.

---

VIII. Complications & Prognosis

Severe Clinical Complications

Surviving the initial viral assault does not guarantee safety. The cascade of complications is vast:

• Pulmonary Decompensation: This is the most feared and common problem, as the lungs fill with protein-rich fluid.
• ARDS: Occurs in approximately 16% of all patients, marking the transition to critical illness.
• Intensive Care Sequelae: Prolonged intubation and ICU stays invite secondary disasters:
  • Nosocomial Infections: Hospital-acquired pathogens causing Ventilator-Associated Pneumonia (VAP) or deadly bloodstream sepsis.
  • Tension Pneumothorax: A catastrophic complication resulting from ventilation at high peak inspiratory pressures, causing the stiff, brittle lung tissue to rupture, trapping air in the chest cavity and crushing the heart.
  • Non-cardiogenic Pulmonary Edema: Widespread fluid leaking into the lungs purely from capillary inflammation, independently of heart failure.

Prognosis & Independent Risk Factors

The virus does not kill equally. Mortality and clinical outcomes are heavily stratified based on specific demographic and biochemical markers:

• Age-Dependent Mortality:
  • Less than 1% mortality in healthy persons under 24 years of age.
  • Greater than 50% mortality in persons over 65 years of age.
• Established Poor Prognostic Factors Include:
  • Advanced age (The single greatest risk factor).
  • Pregnancy (Especially devastating during the third trimester, leading to high maternal mortality and spontaneous abortion).
  • Chronic Hepatitis B infection treated with Lamivudine: This indicates an already stressed hepatic system and an immunocompromised state.
  • High initial or peak Lactate Dehydrogenase (LDH) concentrations (correlating with the sheer volume of destroyed tissue).
  • High absolute neutrophil count on initial presentation.
  • The presence of underlying comorbidities: specifically Diabetes mellitus, cardiovascular disease, and acute/chronic kidney disease.
  • Abnormally low counts of CD4 and CD8 T-cells on presentation, indicating a severely crippled adaptive immune system unable to mount a defense.

---

IX. References